5 questions answered from cited research · Plain language
Yes, saliva samples can help predict nasopharyngeal carcinoma (NPC) risk by detecting EBV markers and microbial changes, but they are not yet standard for other cancers.
Read the full answer →No, intravenous vitamin C did not reduce stomach problems during chemotherapy for nasopharyngeal carcinoma in a clinical trial.
Read the full answer →Antibodies to Epstein-Barr virus (EBV) proteins, especially EBNA1, and circulating EBV DNA are linked to higher NPC risk.
Read the full answer →Yes, helical tomotherapy (a form of IMRT) significantly reduces dry mouth (xerostomia) in nasopharyngeal carcinoma patients by sparing salivary glands, with low rates of severe xerostomia.
Read the full answer →Yes, a specific saliva test measuring IgA antibodies to EBNA1 protein can accurately predict NPC risk, with sensitivity up to 90% and specificity over 91%.
Read the full answer →